SCHEMBL1344670

SCHEMBL1344670

C[CH]Oc1ccc(C(N)=O)cc1

nearest known ligand 0.63

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 19/20 0.63
PARP2 Q9UGN5 3/20 0.63
PARP4 Q9UKK3 2/20 0.63
CA1 P00915 1/20 0.63
CA2 P00918 1/20 0.63
PARP1 P09874 1/20 0.63
PARP15 Q460N3 4/20 0.61
PARP14 Q460N5 2/20 0.61
ALDH1A1 P00352 1/20 0.61
KMT2A Q03164 1/20 0.61
PARP16 Q8N5Y8 1/20 0.61
PARP11 Q9NR21 1/20 0.61
PARP3 Q9Y6F1 1/20 0.53
TNKS O95271 1/20 0.47
TNKS2 Q9H2K2 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9243495 0.83 CA1 (0.59) PARP10CA1CA2PARP15ALDH1A1
SCHEMBL9633891 0.83 PARP10 (0.61) PARP10PARP2PARP4CA1CA2
Terephthalamide SCHEMBL28194749 0.81 PARP10 (0.58) PARP10PARP2PARP4CA1CA2
SCHEMBL28554610 0.81 PARP10 (0.59) PARP10PARP2PARP4CA1CA2
SCHEMBL201761 0.77 PARP10 (1.00) PARP10PARP2PARP4CA1CA2
SCHEMBL3137816 0.77 PARP10 (1.00) PARP10PARP2PARP4CA1CA2
Hydrochloric Acid SCHEMBL408766 0.76 PARP10 (0.95) PARP10PARP2PARP4CA1CA2
Hydrochloric Acid SCHEMBL4376056 0.76 PARP10 (0.95) PARP10PARP2PARP4CA1CA2
Terephthalamide SCHEMBL23774 0.75 PARP1 (0.71) PARP10PARP2PARP4CA1CA2
SCHEMBL8747591 0.75 CA1 (0.59) CA1CA2ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063093-B2 Derivatives of 5-(halo)alkanoyl-6-hydroxy- benozofuran, benzothiophene, or indole; autoimmune diseases; systemic lupus erythematosis, rheumatoid arthritis, multiple sclerosis and psoriasis, transplant rejection; antiproliferative, anticarcinogenic, antidiabetic, antiinflammatory and antiulcer agents HARVEY ANDREW J (AU) 2011-11-22 US claimed
US-20080221194-A1 Novel Potassium channel Blockers and Uses Thereof HARVEY ANDREW J 2008-09-11 US claimed
WO-2006096911-A1 NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF HARVEY ANDREW J (AU) 2006-09-21 WO claimed
US-8063093-B2 Derivatives of 5-(halo)alkanoyl-6-hydroxy- benozofuran, benzothiophene, or indole; autoimmune diseases; systemic lupus erythematosis, rheumatoid arthritis, multiple sclerosis and psoriasis, transplant rejection; antiproliferative, anticarcinogenic, antidiabetic, antiinflammatory and antiulcer agents HARVEY ANDREW J (AU) 2011-11-22 US disclosed
US-20080221194-A1 Novel Potassium channel Blockers and Uses Thereof HARVEY ANDREW J 2008-09-11 US disclosed
US-4604481-A Compounds for treatment or prophylaxis of cardiac disorders AMERICAN HOSPITAL SUPPLY CORPORATION (US) 1986-08-05 US disclosed
US-4405642-A BETA-BLOCKING AROMATIC ESTER COMPOUND AMERICAN HOSPITAL SUPPLY CORPORATION (US) 1983-09-20 US disclosed
EP-0065964-A4 METHOD FOR TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS. AMERICAN HOSPITAL SUPPLY CORP (US) 1983-04-06 EP disclosed
EP-0065964-A1 METHOD FOR TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS. AMERICAN HOSPITAL SUPPLY CORP (US) 1982-12-08 EP disclosed
WO-1982001868-A1 METHOD FOR TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS AMERICAN HOSPITAL SUPPLY CORP (US) 1982-06-10 WO disclosed
EP-0053436-A1 Method for treatment or prophylaxis of cardiac disorders AMERICAN HOSPITAL SUPPLY CORPORATION (US) 1982-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221194-A1 Novel Potassium channel Blockers and Uses Thereof KCNAB1, KCNB1, KCNMB1 PARP10 2309/4885PARP2 4028/4885PARP4 3260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.